More PML problems from Adcetris
A pair of new cases involving progressive multifocal leukoencephalopathy (PML), a potentially fatal brain virus, have been reported to the Food & Drug Administration in patients who were receiving the recently approved Hodgkin lymphoma treatment Adcetris (previously known as SGN-35).
This brings the total known number of diagnoses in patients after receiving the antibody conjugate treatment to three.
This has prompted the FDA to order a black box warning to appear on the drug's label.
Adcetris is not the first recently approved drug to see some of its patients develop PML, including Tysabri, cladribine, and Rituxan. It is believed that PML is a result of the reactivation of latent infection with the JC virus.
Symptoms tend to resemble those of Alzheimer's: mood changes, behavioral changes, weakness, cognition problems, and problems with speaking, seeing and walking.
Source: FDA
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
